|Assessment Status||Assessment Process Complete|
|Indication||For the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.|
|Rapid review commissioned||12/09/2013|
|Rapid review completed||02/10/2013|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended|
|Full submission received from Applicant||14/02/2014|
|NCPE assessment completed||30/06/2014|
|NCPE assessment outcome||Reimbursement not Recommended|
The NCPE does not recommend regorafenib (Stivarga®) as a cost-effective treatment option.
Following discussions between the HSE and the company, regorafenib is now reimbursed under a patient access scheme.